The search for animal models for Lassa fever vaccine development

Expert Review of Vaccines

Volumn 12, Issue 1, 2013, Pages 71-86

  Lukashevich, Igor S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

animal models; Lassa fever; vaccine research and development

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CANDID 1; CHIMERIVAX; DNA VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN M ANTIBODY; INACTIVATED VIRUS VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 8; LASSA FEVER VACCINE; LIVE VACCINE; PEPTIDE VACCINE; PLACEBO; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ADAPTIVE IMMUNITY; AFRICA; ANIMAL MODEL; ARGENTINE HEMORRHAGIC FEVER; BIOLOGICAL WARFARE; CALLITRICHINAE; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; GOVERNMENT REGULATION; HUMAN; IMMUNOGENICITY; INFECTION SENSITIVITY; INNATE IMMUNITY; LASSA FEVER; LASSA VIRUS; MACACA FASCICULARIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; REPLICON; RESEARCH ETHICS; REVIEW; RHESUS MONKEY; SYRIAN HAMSTER; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

AFRICA, WESTERN; ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; HUMANS; LASSA FEVER; LASSA VIRUS; MICE; RATS; VIRAL VACCINES;

EID: 84871599547     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.139     Document Type: Review

References (145)

1. McCormick JB, Fisher-Hoch SP. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75-109 (2002).
2. Khan SH, Goba A, Chu M et al.; Mano River Union Lassa Fever Network. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 78(1), 103-115 (2008).
3. Fichet-Calvet E, Rogers DJ. Risk maps of Lassa fever in West Africa. PLoS Negl. Trop. Dis. 3(3), e388 (2009).
4. Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327(7426), 1271-1275 (2003).
5. Safronetz D, Lopez JE, Sogoba N et al. Detection of Lassa virus, Mali. Emerging Infect. Dis. 16(7), 1123-1126 (2010).
6. Andersen KG, Shylakhter I, Tabrizi S, Grossman SR, Happi CT, Sabeti PC. Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 367(1590), 868-877 (2012).
7. Sabeti PC, Varilly P, Fry B et al.; International HapMap Consortium. Genome-wide detection and characterization of positive selection in human populations. Nature 449(7164), 913-918 (2007).
8. Lukashevich IS, Stelmakh TA, Golubev VP, Stchesljenok EP, Lemeshko NN. Ribonucleic acids of Machupo and Lassa viruses. Arch. Virol. 79(3-4), 189-203 (1984).
9. Djavani M, Lukashevich IS, Sanchez A, Nichol ST, Salvato MS. Completion of the Lassa fever virus sequence and identifica-tion of a RING finger open reading frame at the L RNA 5′ End. Virology 235(2), 414-418 (1997).
10. Lukashevich IS, Djavani M, Shapiro K et al. The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J. Gen. Virol. 78(Pt 3), 547-551 (1997).
11. Strecker T, Eichler R, Meulen J et al. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J. Virol. 77(19), 10700-10705 (2003).
12. Auperin DD, Sasso DR, McCormick JB. Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology 154(1), 155-167 (1986).
13. Clegg JC, Wilson SM, Oram JD. Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products. Virus Res. 18(2-3), 151-164 (1991).
14. Cao W, Henry MD, Borrow P et al. Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282(5396), 2079-2081 (1998).
15. Rojek JM, Moraz ML, Pythoud C et al. Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. Cell. Microbiol. 14(7), 1122-1134 (2012).
16. Shimojima M, Str?er U, Ebihara H, Feldmann H, Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J. Virol. 86(4), 2067-2078 (2012).
17. Shimojima M, Kawaoka Y. Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus glycoprotein. J. Vet. Med. Sci. 74(10), 1363-1366 (2012).
18. Glushakova SE, Omelyanenko VG, Lukashevitch IS et al. The fusion of artificial lipid membranes induced by the synthetic arenavirus 'fusion peptide'. Biochim. Biophys. Acta 1110(2), 202-208 (1992).
19. Klewitz C, Klenk HD, ter Meulen J. Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. J. Gen. Virol. 88(Pt 8), 2320-2328 (2007).
20. Kunz S. Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction. Virology 387(2), 245-249 (2009).
21. Pasqual G, Rojek JM, Masin M, Chatton JY, Kunz S. Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog. 7(9), e1002232 (2011).
22. Salvato MS, Clegg JCS, Buchmeier MJ et al. Family Arenaviridae, Virus Taxonomy, Classification and Nomenclature of Viruses, Ninth Report of the International Committee on Taxonomy of Viruses. King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Elsevier Inc., MA, USA, 715-723 (2012).
23. Lecompte E, ter Meulen J, Emonet S, Daffis S, Charrel RN. Genetic identification of Kodoko virus, a novel arenavirus of the African pigmy mouse (Mus Nannomys minutoides) in West Africa. Virology 364(1), 178-183 (2007).
24. Paweska JT, Sewlall NH, Ksiazek TG et al.; Outbreak Control and Investigation Teams. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerging Infect. Dis. 15(10), 1598-1602 (2009).
25. Briese T, Paweska JT, McMullan LK et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 5(5), e1000455 (2009).
26. Ishii A, Thomas Y, Moonga L et al. Novel arenavirus, Zambia. Emerging Infect. Dis. 17(10), 1921-1924 (2011).
27. Palacios G, Savji N, Hui J et al. Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J. Gen. Virol. 91(Pt 5), 1315-1324 (2010).
28. Coulibaly-N'Golo D, Allali B, Kouassi SK et al. Novel arenavirus sequences in Hylomyscus sp. and Mus (Nannomys) setulosus from Ce d'Ivoire: implications for evolution of arenaviruses in Africa. PLoS ONE 6(6), e20893 (2011).
29. Bowen MD, Rollin PE, Ksiazek TG et al. Genetic diversity among Lassa virus strains. J. Virol. 74(15), 6992-7004 (2000).
30. Lozano ME, Posik DM, Albari CG et al. Characterization of arenaviruses using a family-specific primer set for RT-PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses. Virus Res. 49(1), 79-89 (1997).
31. Bowen MD, Peters CJ, Nichol ST. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol. Phylogenet. Evol. 8(3), 301-316 (1997).
32. Gther S, Emmerich P, Laue T et al. Imported Lassa fever in Germany: molecular characterization of a new Lassa virus strain. Emerging Infect. Dis. 6(5), 466-476 (2000).
33. Fisher-Hoch SP, McCormick JB. Lassa fever vaccine. Expert Rev. Vaccines 3(2), 189-197 (2004).
34. McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J. Med. Virol. 37(1), 1-7 (1992).
35. Branco LM, Grove JN, Geske FJ et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J. 7, 279 (2010).
36. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
37. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 20(1), 17-22 (2008).
38. Borrow P, Martez-Sobrido L, de la Torre JC. Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses 2(11), 2443-2480 (2010).
39. Koyama S, Coban C, Aoshi T, Horii T, Akira S, Ishii KJ. Innate immune control of nucleic acid-based vaccine immunogenicity. Expert Rev. Vaccines 8(8), 1099-1107 (2009).
40. Huang C, Kolokoltsova OA, Yun NE et al. Junvirus infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl. Trop. Dis. 6(5), e1659 (2012).
41. Boesen A, Sundar K, Coico R. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice. Clin. Diagn. Lab. Immunol. 12(10), 1223-1230 (2005).
42. Botten J, Alexander J, Pasquetto V et al. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol. 80(17), 8351-8361 (2006).
43. Botten J, Whitton JL, Barrowman P et al. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J. Virol. 84(19), 9947-9956 (2010).
44. Liu F, Feuer R, Hassett DE, Whitton JL. Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8 T cell-mediated, TNF-dependent immunopathology. J. Clin. Invest. 116(2), 465-475 (2006).
45. Meulen J, Badusche M, Satoguina J et al. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321(1), 134-143 (2004).
46. ter Meulen J, Badusche M, Kuhnt K et al. Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J. Virol. 74(5), 2186-2192 (2000).
47. Rodriguez-Carreno MP, Nelson MS, Botten J, Smith-Nixon K, Buchmeier MJ, Whitton JL. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335(1), 87-98 (2005).
48. Whitton JL, Sheng N, Oldstone MB, McKee TA. A 'string-of-beads' vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J. Virol. 67(1), 348-352 (1993).
49. Grant-Klein RJ, Altamura LA, Schmaljohn CS. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses. Virus Res. 162(1-2), 148-161 (2011).
50. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28(6), 573-579 (2010).
51. Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A. Argentine hemorrhagic fever vaccines. Hum. Vaccin. 7(6), 694-700 (2011).
52. Clegg JC, Lloyd G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2(8552), 186-188 (1987).
53. Auperin DD, Esposito JJ, Lange JV et al. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res. 9(2-3), 233-248 (1988).
54. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for Lassa fever. J. Virol. 74(15), 6777-6783 (2000).
55. Garbutt M, Liebscher R, Wahl-Jensen V et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78(10), 5458-5465 (2004).
56. Geisbert TW, Jones S, Fritz EA et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2(6), e183 (2005).
57. Lukashevich IS. Generation of reassortants between African arenaviruses. Virology 188(2), 600-605 (1992).
58. Lukashevich IS, Patterson J, Carrion R et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79(22), 13934-13942 (2005).
59. Lukashevich IS, Carrion R Jr, Salvato MS et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26(41), 5246-5254 (2008).
60. Bredenbeek PJ, Molenkamp R, Spaan WJ et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345(2), 299-304 (2006).
61. Jiang X, Dalebout TJ, Bredenbeek PJ et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29(6), 1248-1257 (2011).
62. Pinschewer DD, Flatz L, Steinborn R et al. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes. Int. Immunol. 22(9), 749-756 (2010).
63. Emonet SE, Urata S, de la Torre JC. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology 411(2), 416-425 (2011).
64. Carnec X, Baize S, Reynard S et al. Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages. J. Virol. 85(22), 12093-12097 (2011).
65. Kerber R, Rieger T, Busch C et al. Cross-species analysis of the replication complex of Old World arenaviruses reveals two nucleoprotein sites involved in L protein function. J. Virol. 85(23), 12518-12528 (2011).
66. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28(3), 632-649 (2010).
67. Editorial. YF17D vector for Lassa fever vaccine. Int. Innovation 77-79 (2010).
68. Vander Veen RL, Hank Harris DL, Kamrud KI. Alphavirus replicon vaccines. Animal Health Res. Rev. doi:10.1017/S1466252312000011 (2012) (Epub ahead of Print).
69. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75(23), 11677-11685 (2001).
70. Balasuriya UB, Heidner HW, Davis NL et al. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20(11-12), 1609-1617 (2002).
71. Norbury CC, Basta S, Donohue KB et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304(5675), 1318-1321 (2004).
72. Huckriede A, Bungener L, Holtrop M et al. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 22(9-10), 1104-1113 (2004).
73. Schliehe C, Bitzer A, van den Broek M, Groettrup M. Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J. Virol. 86(18), 9782-9793 (2012).
74. McKee KTJ, Enria DA, Barerra-Oro JG. Junin argentine hemorrhagic fever. In: Vaccines for Biodefense and Energing and Neglected Diseases. Barett ADT, Stanberry LR (Eds). Elsevier, Amsterdam, The Netherlands 537-550 (2009).
75. Snoy PJ. Establishing efficacy of human products using animals: the US food and Drug Administration's 'Animal Rule'. Vet. Pathol. 47(5), 774-778 (2010).
76. Bausch DG, Rollin PE, Demby AH et al. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescentantibody test, and virus isolation. J. Clin. Microbiol. 38(7), 2670-2677 (2000).
77. Branco LM, Grove JN, Boisen ML et al. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol. J. 8, 478 (2011).
78. Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans. R. Soc. Trop. Med. Hyg. 79(3), 380-384 (1985).
79. Jahrling PB. Protection of Lassa virusinfected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J. Med. Virol. 12(2), 93-102 (1983).
80. Jahrling PB, Peters CJ. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect. Immun. 44(2), 528-533 (1984).
81. Moraz ML, Kunz S. Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev. Anti. Infect. Ther. 9(1), 49-59 (2011).
82. Walker DH, McCormick JB, Johnson KM et al. Pathologic and virologic study of fatal Lassa fever in man. Am. J. Pathol. 107(3), 349-356 (1982).
83. Knobloch J, McCormick JB, Webb PA, Dietrich M, Schumacher HH, Dennis E. Clinical observations in 42 patients with Lassa fever. Tropenmed. Parasitol. 31(4), 389-398 (1980).
84. McCormick JB, Walker DH, King IJ et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am. J. Trop. Med. Hyg. 35(2), 401-407 (1986).
85. Asper M, Sternsdorf T, Hass M et al. Inhibition of different Lassa virus strains by α and γ interferons and comparison with a less pathogenic arenavirus. J. Virol. 78(6), 3162-3169 (2004).
86. Baize S, Pannetier D, Faure C et al. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 8(5), 1194-1202 (2006).
87. Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 172(5), 2861-2869 (2004).
88. Baize S, Marianneau P, Loth P et al. Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J. Virol. 83(11), 5890-5903 (2009).
89. Hayes MW, Carrion R Jr, Nunneley J, Medvedev AE, Salvato MS, Lukashevich IS. Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro. J. Virol. 86(13), 7216-7226 (2012).
90. Lukashevich IS, Maryankova R, Vladyko AS et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-α gene expression. J. Med. Virol. 59(4), 552-560 (1999).
91. Mahanty S, Bausch DG, Thomas RL et al. Low levels of interleukin-8 and interferoninducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J. Infect. Dis. 183(12), 1713-1721 (2001).
92. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170(6), 2797-2801 (2003).
93. Jahrling PB, Frame JD, Smith SB, Monson MH. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans. R. Soc. Trop. Med. Hyg. 79(3), 374-379 (1985).
94. Korch J Jr. Animal models: what do we know and where do we go? Animal Models Development Workshop. Bethesda, MD, USA, 17-18 September 2012.
95. Walker DH, Wulff H, Lange JV, Murphy FA. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 52(4-6), 523-534 (1975).
96. Jahrling PB, Smith S, Hesse RA, Rhoderick JB. Pathogenesis of Lassa virus infection in guinea pigs. Infect. Immun. 37(2), 771-778 (1982).
97. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT Jr, Barrera Oro JG. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 134, 5-68 (1987).
98. Carrion R Jr, Brasky K, Mansfield K et al. Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J. Virol. 81(12), 6482-6490 (2007).
99. Lukashevich IS, Tikhonov I, Rodas JD et al. Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. J. Virol. 77(3), 1727-1737 (2003).
100. Lukashevich IS, Rodas JD, Tikhonov II et al. LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch. Virol. 149(12), 2319-2336 (2004).
101. Goicochea MA, Zapata JC, Bryant J, Davis H, Salvato MS, Lukashevich IS. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine 30(8), 1445-1452 (2012).
102. Oldstone MB. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr. Top. Microbiol. Immunol. 263, 83-117 (2002).
103. Buckley SM, Casals J. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am. J. Trop. Med. Hyg. 19(4), 680-691 (1970).
104. Lukashevich IS. Lassa virus lethality for inbred mice. Ann. Soc. Belg. Med. Trop. 65(2), 207-209 (1985).
105. Wulff H, McIntosh BM, Hamner DB, Johnson KM. Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. Bull. World Health Organ. 55(4), 441-444 (1977).
106. Lukashevich IS, Vasiuchkov AD, Stel'makh TA, Scheslenok EP, Shabanov AG. [The isolation and characteristics of reassortants between the Lassa and Mopeia arenaviruses]. Vopr. Virusol. 36(2), 146-150 (1991).
107. Lukashevich IS. Human Pathogens of the Arenaviridae family. Sov. Med. Rev. Harwood Academic Publishers GmbH, UK 133-186 (1987).
108. Lukashevich IS , Vela EM. Pathogenesis of Lassa virus infection in experimental animals. In: Molecular Pathogenesis of Hemorrhagic Fever Viruses. Vela EM (Ed). Transw. Res. Net. Kerala, India, 101-142 (2010).
109. McGavern DB, Homann D, Oldstone MB. T cells in the central nervous system: the delicate balance between viral clearance and disease. J. Infect. Dis. 186(Suppl. 2), S145-S151 (2002).
110. Barkar ND, Lukashevich IS. [Lassa and Mozambique viruses: cross protection in experiments on mice and action of immunosuppressants on experimental infections]. Vopr. Virusol. 34(5), 598-603 (1989).
111. Kolokoltsova OA, Yun NE, Poussard AL et al. Mice lacking α/β and γ interferon receptors are susceptible to junin virus infection. J. Virol. 84(24), 13063-13067 (2010).
112. Gowen BB, Wong MH, Larson D et al. Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS ONE 5(9), e12760 (2010).
113. Bradfute SB, Stuthman KS, Shurtleff AC, Bavari S. A STAT-1 knockout mouse model for Machupo virus pathogenesis. Virol. J. 8, 300 (2011).
114. Yun NE, Poussard AL, Seregin AV et al. Functional interferon system is required for clearance of Lassa virus. J. Virol. 86(6), 3389-3392 (2012).
115. Camus GS, Qui X, Bente DA, Strong UC, Jones SM. Resistance to a Lassa virus infection is interferon-dependent, but not B or T cell-mediated in mice. In: The 28th ASV Annual Meeting, Scientific Program and Abstract. Vancouver, BC, Canada, 11-15 July 2009.
116. Martez-Sobrido L, Giannakas P, Cubitt B, Garc-Sastre A, de la Torre JC. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 81(22), 12696-12703 (2007).
117. Flatz L, Rieger T, Merkler D et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 6(3), e1000836 (2010).
118. Firsova IV, Shatokhina IV, Borisevich IV et al. [Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever]. Vopr. Virusol. 48(6), 43-45 (2003).
119. Callis RT, Jahrling PB, DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am. J. Trop. Med. Hyg. 31(5), 1038-1045 (1982).
120. Fisher-Hoch SP, Mitchell SW, Sasso DR, Lange JV, Ramsey R, McCormick JB. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J. Infect. Dis. 155(3), 465-474 (1987).
121. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141(5), 580-589 (1980).
122. Peters CJ. Arenaviruses. In: Clinical Virology. Richman DD, Whitley RJ, Hayden FG (Eds). Churchill Livingstone, New York, NY, USA 779-799 (1997).
123. Walker DH, Johnson KM, Lange JV, Gardner JJ, Kiley MP, McCormick JB. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J. Infect. Dis. 146(3), 360-368 (1982).
124. Hensley LE, Smith MA, Geisbert JB et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 8, 205 (2011).
125. Baize S, Marianneau P, Loth P et al. Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J. Virol. 83(11), 5890-5903 (2009).
126. Pannetier D, Reynard S, Russier M et al. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J. Virol. 85(16), 8293-8306 (2011).
127. Geisbert TW, Daddario-Dicaprio KM, Lewis MG et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 4(11), e1000225 (2008).
128. Carrion R Jr, Patterson JL. Vaccines against viral hemorrhagic fevers: non-human primate models. Hum. Vaccin. 7(6), 667-673 (2011).
129. Mansfield K. Marmoset models commonly used in biomedical research. Comp. Med. 53(4), 383-392 (2003).
130. Gowen BB, Holbrook MR. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 78(1), 79-90 (2008).
131. Omatsu T, Moi ML, Hirayama T et al. Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J. Gen. Virol. 92(Pt 10), 2272-2280 (2011).
132. Aronson JF, Herzog NK, Jerrells TR. Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains. Am. J. Pathol. 145(1), 228-235 (1994).
133. Scott EP, Aronson JF. Cytokine patterns in a comparative model of arenavirus haemorrhagic fever in guinea pigs. J. Gen. Virol. 89(Pt 10), 2569-2579 (2008).
134. Bowick GC, Fennewald SM, Zhang L et al. Attenuated and lethal variants of Pichindé virus induce differential patterns of NF-κB activation suggesting a potential target for novel therapeutics. Viral Immunol. 22(6), 457-462 (2009).
135. Liang Y, Lan S, Ly H. Molecular determinants of Pichinde virus infection of guinea pigs-a small animal model system for arenaviral hemorrhagic fevers. Ann. N. Y. Acad. Sci. 1171 (Suppl. 1), E65-E74 (2009).
136. Jahrling PB, Hesse RA, Rhoderick JB, Elwell MA, Moe JB. Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 32(2), 872-880 (1981).
137. Connolly BM, Jenson AB, Peters CJ, Geyer SJ, Barth JF, McPherson RA. Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study. Am. J. Trop. Med. Hyg. 49(1), 10-24 (1993).
138. Gowen BB, Julander JG, London NR et al. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol. J. 7, 240 (2010).
139. Sbrana E, Mateo RI, Xiao SY, Popov VL, Newman PC, Tesh RB. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with Pirital virus (Arenaviridae): a rodent model of Lassa fever. Am. J. Trop. Med. Hyg. 74(6), 1096-1102 (2006).
140. Lukashevich IS, Djavani M, Rodas JD et al. Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J. Med. Virol. 67(2), 171-186 (2002).
141. Johnson RF, Dodd LE, Yellayi S et al. Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. Virology 421(2), 129-140 (2011).
142. Levis R. Regulatory considerations related for the development of filovirus vaccines. J. Vaccines Vaccin. 3(4), 118 (2012).
143. Appaiahgari MB, Vrati S. Clinical development of IMOJEV-a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin. Biol. Ther. 12(9), 1251-1263 (2012).
144. Carrion R Jr, Bredenbeek P, Jiang X et al. Vaccine platforms to control arenaviral hemorrhagic fevers. J. Vaccines Vaccin. (2012) (In Press).
145. Albari CG, Bird BH, Chakrabarti AK, Dodd KA, Erickson BR, Nichol ST. Efficient rescue of recombinant Lassa virus reveals the influence of S segment noncoding regions on virus replication and virulence. J. Virol. 85(8), 4020-4024 (2011).